WaveMan
WaveMan · Company
KURA · Kura Oncology, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

KURA Kura Oncology (KURA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001422143
Quote by TradingView
C-suite buying · 1Form 144 · 12
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
121
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $184.5K priced

What the filings say about KURA

Insiders, 180 days
-$345.8K net sold
1 buyer · 6 sellers · 29% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.7M
12 notices

Kura Oncology insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Kura Oncology, Inc. insiders sold a net $345.8K of stock across 87 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
FORD KATHLEEN
Chief Operating Officer
SELL
2026-09-29 SEC
3,668
$39.4K
-10.2%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Sep 28, 2026.
  • The trade is 2.6% of the 142,986 shares held after it.
  • 5 other insiders sold within 30 days.
  • 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer FORD KATHLEEN sold about $39.4K of KURA under a 10b5-1 plan on Sep 29, 2026; 5 other insiders sold within 30 days and 121 funds added in the latest 13F quarter.
Leoni Mollie
Chief Medical Officer
SELL
2026-09-29 SEC
28,802
$309.6K
-10.2%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Sep 28, 2026.
  • The trade is 20.4% of the 141,095 shares held after it.
  • 5 other insiders sold within 30 days.
  • 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Leoni Mollie sold about $309.6K of KURA on Sep 29, 2026; 5 other insiders sold within 30 days and 121 funds added in the latest 13F quarter.
Powl Brian T.
Chief Commercial Officer
SELL
2026-09-29 SEC
15,430
$165.9K
-10.2%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Sep 28, 2026.
  • The trade is 11.3% of the 136,819 shares held after it.
  • 5 other insiders sold within 30 days.
  • 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Powl Brian T. sold about $165.9K of KURA on Sep 29, 2026; 5 other insiders sold within 30 days and 121 funds added in the latest 13F quarter.
Bair Teresa Brophy
Chief Legal Officer
SELL
2026-09-29 SECtraded 2026-09-28
8,442
$88.6K
-10.2%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Aug 19, 2026.
  • The trade is 4.5% of the 187,002 shares held after it.
  • 5 other insiders sold within 30 days.
  • 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Bair Teresa Brophy sold about $88.6K of KURA under a 10b5-1 plan on Sep 28, 2026; 5 other insiders sold within 30 days and 121 funds added in the latest 13F quarter.
FORD KATHLEEN
Chief Operating Officer
SELL
2026-09-29 SECtraded 2026-09-28
6,906
$72.5K
-10.2%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on May 19, 2026.
  • The trade is 4.7% of the 146,654 shares held after it.
  • 5 other insiders sold within 30 days.
  • 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer FORD KATHLEEN sold about $72.5K of KURA under a 10b5-1 plan on Sep 28, 2026; 5 other insiders sold within 30 days and 121 funds added in the latest 13F quarter.
87 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 82 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$345.8K over 180 days
+$643.0K over 90 days
below 53% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
121 funds bought in last quarter
more than 76% of Pharma & Biotech
Revenue
+25.2% year over year
more than 70% of Pharma & Biotech
Margin
-412.9% net margin
below 76% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
20.4% of the float short (float per yahoo 2026-10-26) · 7.7 days to cover · settled 2026-09-30
more than 88% of Pharma & Biotech
What changed in the last 30 days
Sep 29Chief Medical Officer Leoni Mollie sold $440.2K (2 trades, Sep 28 to Sep 29)
Sep 29Chief Commercial Officer Powl Brian T. sold $345.0K (3 trades, Sep 28 to Sep 29)
Sep 29Officer MOLLIE LEONI filed to sell $305.6K by Sep 29 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Sep 29Officer BRIAN POWL filed to sell $163.7K by Sep 29 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Sep 29Chief Operating Officer FORD KATHLEEN sold $111.9K under a 10b5-1 plan (2 trades, Sep 28 to Sep 29)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.

Watch KURA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+5.7%12M
-19%+4%+27%+49%2025-102025-122026-022026-042026-062026-082026-10 2026-08-24 · WILSON TROY EDWARD bought $1.2M2026-08-17 · WILSON TROY EDWARD bought $1.1M2026-06-18 · Leoni Mollie sold $834.0K2026-08-19 · Bair Teresa Brophy sold $397.7K2026-09-29 · Leoni Mollie sold $309.6K2025-12-18 · Burrows Francis sold $232.0K2026-09-24 · Burrows Francis sold $224.5K2025-11-14 · Leoni Mollie sold $173.1K2026-09-29 · Powl Brian T. sold $165.9K2026-09-28 · Leoni Mollie sold $130.7K2026-05-21 · Powl Brian T. sold $110.0K2025-12-09 · Hasnain Faheem sold $109.8K2025-11-14 · Powl Brian T. sold $99.4K2025-11-14 · Bair Teresa Brophy sold $98.4K2026-09-28 · Powl Brian T. sold $94.7K2026-09-28 · Bair Teresa Brophy sold $88.6K2026-09-28 · Powl Brian T. sold $84.5K2025-11-14 · FORD KATHLEEN sold $77.2K2026-09-28 · FORD KATHLEEN sold $72.5K2026-08-21 · Powl Brian T. sold $51.7K2025-11-14 · DOYLE THOMAS JAMES sold $50.7K2026-09-28 · DOYLE THOMAS JAMES sold $48.4K2026-01-27 · Powl Brian T. sold $41.0K2026-01-27 · Bair Teresa Brophy sold $40.4K2026-09-29 · FORD KATHLEEN sold $39.4K2026-01-27 · Bair Teresa Brophy sold $34.7K2026-01-27 · Leoni Mollie sold $30.9K2026-05-18 · Bair Teresa Brophy sold $21.2K2026-05-19 · FORD KATHLEEN sold $20.5K2026-01-27 · Bair Teresa Brophy sold $19.8K2026-01-27 · Leoni Mollie sold $18.9K2026-01-27 · DOYLE THOMAS JAMES sold $18.8K2026-01-27 · FORD KATHLEEN sold $15.3K2026-01-27 · Powl Brian T. sold $13.3K2026-01-27 · Leoni Mollie sold $11.3K2026-01-27 · Burrows Francis sold $11.1K2026-01-27 · DOYLE THOMAS JAMES sold $9.4K2026-01-27 · Leoni Mollie sold $8.0K2026-01-27 · DOYLE THOMAS JAMES sold $7.5K2026-01-27 · DOYLE THOMAS JAMES sold $5.9K2026-05-19 · Powl Brian T. sold $3.1K2026-09-29 · KATHLEEN FORD filed to sell $38.9K2026-09-29 · MOLLIE LEONI filed to sell $305.6K2026-09-29 · BRIAN POWL filed to sell $163.7K2026-09-28 · BAIR TERESA BROPHY filed to sell $90.8K2026-09-28 · DOYLE THOMAS JAMES filed to sell $49.6K2026-09-28 · FORD KATHLEEN filed to sell $74.3K2026-09-28 · LEONI MOLLIE filed to sell $133.9K2026-09-28 · POWL BRIAN T filed to sell $97.1K2026-09-28 · BRIAN POWL filed to sell $86.1K2026-09-24 · FRANCIS J BURROWS filed to sell $224.5K2026-08-21 · BRIAN POWL filed to sell $50.9K2026-08-19 · TERESA BAIR filed to sell $388.2K2026-06-18 · MOLLIE VANESSA LEONI filed to sell $812.8K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns KURA: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
10,509,233 sh
$115.3M
MONTANOVA CAPITAL, LLC
8,575,422 sh
$94.1M
BVF INC/IL
8,445,769 sh
$92.7M
STATE STREET CORP
5,329,208 sh
$58.5M
VANGUARD CAPITAL MANAGEMENT LLC
3,916,164 sh
$43.0M

Congress trades in KURA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

KURA planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
KATHLEEN FORD
Filed 2026-09-29
$38.9K
MOLLIE LEONI
Filed 2026-09-29
$305.6K
BRIAN POWL
Filed 2026-09-29
$163.7K
BAIR TERESA BROPHY
Filed 2026-09-28
$90.8K
DOYLE THOMAS JAMES
Filed 2026-09-28
$49.6K

KURA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Etf
$1.4M position · as of 2026-07-31
1.4%
iShares Genomics Immunology and Healthcare ETF
$1.7M position · as of 2026-07-31
0.9%
ALPS Medical Breakthroughs ETF
$928.7K position · as of 2026-05-31
0.6%
NVIT Small Cap Value Fund
$1.2M position · as of 2026-06-30
0.5%
NVIT Multi-Manager Small Company Fund
$1.5M position · as of 2026-06-30
0.3%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$34.1M position · as of 2026-06-30
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
16 registered trials, 6 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
6
Phase 1
4 active
5
Phase 2
0 active
1
Phase 3
1 active
2
Not applicable
0 active
2
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$4.7M
$6.5M
$2.3M
-16%
n/a
2024
$6.2M
$4.2M
$2.4M
-30%
n/a
2023
$5.3M
$5.9M
$2.2M
+16%
n/a
2022
$5.3M
$3.9M
$2.5M
-10%
+14%
2021
$8.7M
-$3.6M
$3.6M
+2%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $345.8K sold by insiders over 180 days, 121 funds added last quarter, $1.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

KURA financials

Revenue growth
+25.2%
XBRL, annual
Net margin
-412.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$77.2M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-384.3%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$117.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.20x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
-11.42x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
-167.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-46.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-60.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$795.3M
market value at close 2026-10-26 on 2026-08-07 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-13.7%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$67.5M$53.9M$0n/a
Operating income-$303.6M-$193.2M-$165.8M-$139.9M
Net income-$278.7M-$174.0M-$152.6M-$135.8M
EPS (diluted)-3.18-2.02-2.08-2.03
Operating cash flow-$64.1M$134.3M-$124.8M-$110.1M
Cash$149.1M$224.5M$37.3M$51.8M
Long-term debt$9.7M$6.9M$9.3M$9.2M
SEC XBRL, fiscal years, as known on 2026-10-28

KURA Stock Sonar score 6/7 axes

Find similar shapesCompare

KURA ranks highest on institutional and government (76th percentile) and growth (70th), and lowest on risk and compliance (12th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
36
Inputs
  • Return on equity-167.7% · 20 pct, sector of 545
  • Return on assets-46.7% · 46 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-60.9% · 42 pct, sector of 576
Financial health
34
Inputs
  • Debt to equity0.20x · 45 pct, sector of 352
  • Cash flow to debt-11.42x · 22 pct, sector of 371
Growth
70
Inputs
  • Revenue growth, YoY+25.2% · 70 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
69
Inputs
  • Net Form 4 buying (codes P and S), 180d$304K · 82 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
76
Inputs
  • Funds adding, latest quarter121 · 76 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
12
Inputs
  • Short interest, % of float+20.4% · 14 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+25.3% · 10 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

KURA filings, in plain words

Are Kura Oncology insiders buying or selling KURA?

In the 180 days to 2026-10-28, Kura Oncology insiders were net sellers, a net $345.8K: $2.4M of purchases and $2.7M of sales reported on Form 4, by 1 buyer and 6 sellers.

Are there planned insider sales of KURA?

Yes. 12 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.7M of stock; the latest, by KATHLEEN FORD, was filed 2026-09-29.

Read the full summary

In the 180 days to 2026-10-28, Kura Oncology insiders were net sellers of KURA, a net $345.8K across purchases and sales reported on Form 4 by 1 buyer and 6 sellers. 29% of the 17 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 12 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies